Yasmin Alam

825 total citations
8 papers, 457 citations indexed

About

Yasmin Alam is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Yasmin Alam has authored 8 papers receiving a total of 457 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Pulmonary and Respiratory Medicine, 3 papers in Oncology and 3 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Yasmin Alam's work include Lung Cancer Treatments and Mutations (4 papers), Corneal Surgery and Treatments (3 papers) and Lung Cancer Diagnosis and Treatment (3 papers). Yasmin Alam is often cited by papers focused on Lung Cancer Treatments and Mutations (4 papers), Corneal Surgery and Treatments (3 papers) and Lung Cancer Diagnosis and Treatment (3 papers). Yasmin Alam collaborates with scholars based in Canada, United Kingdom and Italy. Yasmin Alam's co-authors include Charles Butts, Ian V. Hutchinson, Frances A. Shepherd, Peter Ellis, Eric B. Bell, Duncan McLeod, Edward L. Middleman, Martin R. Weber, David H. Ellison and Harvey Kreisman and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Ophthalmology and Oncotarget.

In The Last Decade

Yasmin Alam

8 papers receiving 446 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yasmin Alam Canada	8	304	206	114	87	86	8	457
Casely Ago Canada	6	184 0.6×	140 0.7×	63 0.6×	40 0.5×	41 0.5×	6	324
Paloma Martín-Martorell Spain	11	279 0.9×	190 0.9×	82 0.7×	28 0.3×	23 0.3×	30	426
J Genollá Spain	11	198 0.7×	82 0.4×	105 0.9×	86 1.0×	134 1.6×	37	447
Cuiling Zhou China	10	253 0.8×	143 0.7×	104 0.9×	16 0.2×	119 1.4×	11	404
Anna Maria Mosconi Italy	13	364 1.2×	90 0.4×	140 1.2×	58 0.7×	27 0.3×	39	558
Michèle Natale Germany	8	293 1.0×	256 1.2×	86 0.8×	19 0.2×	50 0.6×	25	415
Macdonald Js United States	10	248 0.8×	120 0.6×	80 0.7×	20 0.2×	51 0.6×	20	436
Hitomi Sumiyoshi Okuma Japan	11	209 0.7×	109 0.5×	65 0.6×	26 0.3×	66 0.8×	53	336
Robert S. Brody United States	6	269 0.9×	176 0.9×	50 0.4×	24 0.3×	92 1.1×	11	453
Shinichi Togami Japan	15	137 0.5×	85 0.4×	101 0.9×	72 0.8×	133 1.5×	80	597

Countries citing papers authored by Yasmin Alam

Since Specialization

Citations

This map shows the geographic impact of Yasmin Alam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yasmin Alam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yasmin Alam more than expected).

Fields of papers citing papers by Yasmin Alam

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yasmin Alam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yasmin Alam. The network helps show where Yasmin Alam may publish in the future.

Co-authorship network of co-authors of Yasmin Alam

This figure shows the co-authorship network connecting the top 25 collaborators of Yasmin Alam. A scholar is included among the top collaborators of Yasmin Alam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yasmin Alam. Yasmin Alam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Kim, Lucia, Mauro Saieg, Massimo Di Maïo, et al.. (2017). Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients. Oncotarget. 8(34). 57528–57536. 8 indexed citations

Hamm, Caroline, Maher M. El‐Masri, Guillaume Poliquin, et al.. (2011). A Single-Centre Chart Review Exploring the Adjusted Association between Breast Cancer Phenotype and Prognosis. Current Oncology. 18(4). 191–196. 16 indexed citations

Butts, Charles, David Bodkin, Edward L. Middleman, et al.. (2007). Randomized Phase II Study of Gemcitabine Plus Cisplatin or Carboplatin, With or Without Cetuximab, As First-Line Therapy for Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 25(36). 5777–5784. 160 indexed citations

Butts, Charles, David Bodkin, Edward L. Middleman, et al.. (2007). Gemcitabine/platinum alone or in combination with cetuximab as first-line treatment for advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 25(18_suppl). 7539–7539. 14 indexed citations

Arnold, Andrew, Lesley Seymour, Michael Smylie, et al.. (2007). Phase II Study of Vandetanib or Placebo in Small-Cell Lung Cancer Patients After Complete or Partial Response to Induction Chemotherapy With or Without Radiation Therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. Journal of Clinical Oncology. 25(27). 4278–4284. 157 indexed citations

Sheridan, Carl, et al.. (1996). Macrophages during fibrosis following scleral fistulising surgery in a rat model. Current Eye Research. 15(5). 559–568. 11 indexed citations

Hutchinson, Ian V., et al.. (1995). The humoral response to an allograft. Eye. 9(2). 155–160. 11 indexed citations

Alam, Yasmin, et al.. (1992). Prolongation of rat corneal graft survival by treatment with anti-CD4 monoclonal antibody.. British Journal of Ophthalmology. 76(10). 602–606. 80 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact